FDA’s Vaccine Chief to Exit Amid Drug Approval Concerns & Industry Criticism

Prasad’s Exit Follows Industry Concerns Over FDA’s Regulatory Course

Dr. Vinay Prasad, the director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration, will step down from his post at the finish of April. The move comes after a period of mounting criticism regarding the agency’s handling of drug and vaccine approvals, and follows a brief departure from the role last year amid similar concerns. Prasad will return to the University of California San Francisco, where he previously held a professorship in the Department of Epidemiology and Biostatistics, according to an FDA spokesperson.

Prasad simultaneously serves as the agency’s Chief Medical and Scientific Officer, advising the FDA Commissioner and senior officials on medical and scientific issues. His departure marks a significant shift for the FDA, particularly as it navigates a landscape of increasing scrutiny over its regulatory processes. FDA Commissioner Marty Makary stated that Prasad “got a tremendous amount accomplished” during his tenure, as reported by Reuters.

A Pattern of Reversals and Regulatory Uncertainty

The decision to step down follows a series of controversial decisions by the FDA that have sparked unease within the biotechnology and pharmaceutical industries. According to RTW Investments, the agency has, in the past year, either denied or discouraged the approval applications of at least eight drugs, citing issues with the data provided by the companies. This included an initial refusal to review Moderna’s application for a flu vaccine, a decision that was later reversed in February 2026, as CNBC reported.

Companies have voiced concerns that the FDA is shifting its expectations for approval evidence, creating a climate of regulatory uncertainty. This uncertainty, a former FDA official told CNBC, is particularly damaging because companies are receiving one message initially, only to have it changed later in the process. The official spoke on the condition of anonymity.

UniQure and the Huntington’s Disease Treatment

The most recent controversy centered around the FDA’s discouragement of UniQure from applying for expedited approval of its experimental treatment for Huntington’s disease. This decision added to the growing list of concerns regarding the agency’s approach to drug approvals. Huntington’s disease is a progressive brain disorder caused by a genetic defect, and effective treatments are limited.

Broader Backlash and Agency Overhaul

The FDA has faced broader criticism in recent months, fueled in part by staff cuts and an internal overhaul initiated by Health and Human Services Secretary Robert F. Kennedy Jr. Critics worry that these changes could stifle the development of new treatments and potentially compromise patient safety. The Wall Street Journal first reported Prasad’s departure.

Prasad’s Background and Dual Role

Prior to joining the FDA, Dr. Prasad held positions at The University of California at San Francisco and Oregon Health & Science University. His specialty is hematology and oncology, and he previously completed fellowships at the National Cancer Institute and the National Institutes of Health. At the FDA, he held a dual role as both Chief Medical and Scientific Officer and Director of CBER, overseeing the regulation of biological products for human use. As Chief Medical and Scientific Officer, he advised the FDA Commissioner on cross-cutting medical and scientific issues, and fostered partnerships with academic, governmental, and industry stakeholders.

The FDA’s Response: Rigorous Review, Not Rubber-Stamping

In response to the criticism, an FDA spokesperson asserted that there is “no regulatory uncertainty,” stating that the agency “makes decisions based on the evidence, but does not make assurances about outcomes.” The spokesperson emphasized that the FDA is conducting “rigorous, independent reviews and not rubber-stamping approvals.” This statement attempts to address concerns about the agency’s consistency and transparency in its decision-making process.

What’s Next for the FDA and CBER

The FDA has indicated that a successor to Dr. Prasad will be appointed before his departure at the end of April. The agency will necessitate to navigate the ongoing concerns about its regulatory approach while ensuring the continued safety and efficacy of biological products. The appointment of a new CBER director will be closely watched by the industry, as it will signal the FDA’s direction in the coming months. The agency’s ability to restore confidence in its regulatory processes will be crucial for fostering innovation and ensuring access to life-saving treatments.

The search for a replacement will likely focus on candidates with a strong scientific background and a demonstrated commitment to regulatory rigor. The new director will face the challenge of balancing the need for innovation with the imperative of patient safety, a delicate balance that has been at the center of the recent controversies surrounding the FDA.